Centres, groups and projects
Centres, groups and projects
With research grant income of more than £180 million per year, LSHTM is home to a large number of exciting and impactful research activities. We have a global presence with staff conducting research in more than 100 countries and we are deeply committed to working in collaboration with external partners. We are also home to four designated World Health Organization Collaborating Centres.
Featured research
Explore all Centres, groups and projects
W
The is a joint project between the LSHTM and the Natural History Museum (London) providing live schistosome life-cycle stages and their intermediate snail hosts for schistosomiasis research purposes.
We aim to recruit and train the best young clinical and non-clinical scientists with an interest in global health research, to provide them with the support, training and academic environment they need to develop into independent researchers, and to facilitate their academic and clinical career progression.
LSHTM is one of eight WHO Sexually Transmitted Infection (STI) Collaborating Centres worldwide. This Centre is closely aligned with LSHTM’s Sexually Transmitted Infections Research Interest Group (STIRIG), which is made up of more than 50 cross-Faculty, interdisciplinary LSHTM researchers and students conducting research on sexual health and STIs. The Centre works with the , the ), and a network of international collaborators on activities to improve the prevention, control and management of STIs worldwide.
The WOMAN trial, coordinated by the London School of Hygiene & Tropical Medicine (LSHTM) Clinical Trials Unit (CTU) is an international clinical trial of the effect of tranexamic acid on death, hysterectomy and other maternal outcomes, in women with PPH.14.
The World AsthmaPhenotypes Study (WASP) aims to better understand and characterise different sub-types (phenotypes) of asthma.
Our lab is in the Department of Infection Biology (DIB) at the London School of Hygiene and Tropical Medicine (LSHTM) where we research the molecular mechanisms of bacterial pathogenesis and utilise bacteria as biotechnologies for the production of glycoconjugate vaccine candidates against bacterial infectious diseases of global relevance.